LB Pharmaceuticals Inc (LBRX) company profile
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
About LB Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on developing therapies for various neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder. The company’s core effort centers on its lead product candidate, LB-102, a methylated derivative of amisulpride designed as a benzamide antipsychotic drug. LB-102 addresses positive, negative, and cognitive symptoms across clinical evaluations, aiming to serve patients who suffer from persistent psychiatric and mood conditions.
The company maintains its principal executive offices in New York, New York, within the United States. Its clinical pipeline and regulatory activities target patients domestically and internationally, with ongoing late-stage clinical evaluations initiated in the United States. LB Pharmaceuticals conducts research and clinical trials, utilizing third-party manufacturers, service providers, and contract research organizations to support the development and operational scale of its pharmaceutical candidates.
Summary of the business section of LB Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LB Pharmaceuticals Inc
- Headquarters
- New York, NY
- Address
- 575 Madison Avenue 10022
- Phone
- (917) 450-6581
- Website
- lbpharma.us
- Employees
- 27, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, New York
Stock & identifiers
- Ticker
- LBRX
- Exchange
- Nasdaq
- IPO date
- Sep 12, 2025
- Shares outstanding
- 32M, Aug 5, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1691082
- CUSIP
- 50180M108
- ISIN
- US50180M1080
- FIGI
- BBG00XNP5MQ4
- Share class FIGI
- BBG00XNP5MR3
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Heather D. Turner | Chief Executive Officer, Director | – |
| Susan Gani Kozauer | Chief Medical Officer | – |
| Joseph M. Miller | Chief Financial Officer | – |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer | – |
| Marc L. Panoff | Senior Vice President, Finance | 10,242 |
| Gad Soffer | Chief Business Officer | – |
| Anna Eramo | Chief Medical Officer | 3,585 |
| Richard Anthony Silva | SVP, Technical Operations | – |
| Robert R. Ruffolo | Director | 2,365 |
| Rekha Hemrajani | Director | – |
| William P. Kane Jr | Director | – |
| Ran Nussbaum | Director | 1,411,681 |
| Rebecca Luse | Director | – |
| Robert A. Lenz | Director | – |
| J. Scott Garland | Director | – |
| Zachary Prensky | Director | 61,274 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Heather Turner Chief Executive Officer | $568.75K | $321.41K | $10.87M | $129.61K | $11.88M | +148% |
| Gad Soffer Chief Operating and Business Officer | $402.29K | $194.15K | $3.20M | $11.75K | $3.81M | – |
| Anna Eramo Chief Medical Officer | $414.06K | $182.19K | $1.76M | $20.68K | $2.38M | +167% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 12, 2025
- Offer price
- $15.00
- Securities offered
- 19,000,000
- Gross proceeds
- $285.00M
- Exchange
- Nasdaq
- First trading day
- Sep 11, 2025
- First-day close
- $17.30+15.3%
- Lock-up ends (est.)
- Mar 10, 2026
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 12, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 9, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?